Biotech Industry Intelligence

Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure

Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressure

Published

on

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said …​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version